Back to top
more

Journey Medical (DERM)

(Delayed Data from NSDQ)

$6.17 USD

6.17
366,207

+0.42 (7.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $6.16 -0.01 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Journey Medical (DERM) delivered earnings and revenue surprises of -13.33% and 7.57%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 4.62% and 233.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?

by Zacks Equity Research

4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amylyx Pharmaceuticals (AMLX) delivered earnings and revenue surprises of -291.67% and 21.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -59.62% and 0.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA

by Zacks Equity Research

Journey Medical (DERM) stock rises as the FDA accepts its regulatory filing for review seeking approval for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults.

Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

When Journey Medical (DERM) reports fourth-quarter 2023 results, investors will likely focus on the top and bottom-line numbers.

Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B

by Zacks Equity Research

Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.

Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Dr. Reddy's (RDY) reports better-than-expected fiscal third-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.

Novo Nordisk (NVO) Q4 Earnings Top, GLP-1 Drugs Boost Sales

by Zacks Equity Research

Novo Nordisk (NVO) reports better-than-expected fourth-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.

AstraZeneca's (AZN) sBLA for Enhertu Gets FDA's Priority Tag

by Zacks Equity Research

AstraZeneca's (AZN) sBLA for Enhertu to treat metastatic HER2-positive solid tumors gets priority review status by the FDA. A final decision is expected in second-quarter 2024.

Apellis (APLS) Down on Negative CHMP Opinion for Pegcetacoplan

by Zacks Equity Research

Apellis (APLS) stock falls on the CHMP's negative recommendation to the EMA regarding the approval of intravitreal pegcetacoplan in the EU for the treatment of geographic atrophy secondary to age-related macular degeneration.

Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion

by Zacks Equity Research

Heron (HRTX) rises 19% on label expansion of its postoperative pain management drug, Zynrelef, to include additional orthopedic and soft tissue procedures.

Here's What Could Help Journey Medical Corporation (DERM) Maintain Its Recent Price Strength

by Zacks Equity Research

Journey Medical Corporation (DERM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics

by Zacks Equity Research

Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog.

Ahan Chakraborty headshot

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

by Ahan Chakraborty

Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.

argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study

by Zacks Equity Research

argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.

Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA

by Zacks Equity Research

The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.

Kinjel Shah headshot

4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow

by Kinjel Shah

Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.

Invivyd (IVVD) Surges on Positive Data From COVID-19 Study

by Zacks Equity Research

Invivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news.

Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis

by Zacks Equity Research

The FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above.

Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GA

by Zacks Equity Research

The CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines.

Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC

by Zacks Equity Research

Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.

Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409

by Zacks Equity Research

The FDA gives Fast Track designation to Candel's (CADL) lead candidate, CAN-2409 plus prodrug (valacyclovir), for the treatment of patients with pancreatic cancer.

Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.